198 related articles for article (PubMed ID: 29357376)
1. Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.
Li Y; Zhou C; Li J; Liu J; Lin L; Li L; Cao D; Li Q; Wang Z
PLoS One; 2018; 13(1):e0191024. PubMed ID: 29357376
[TBL] [Abstract][Full Text] [Related]
2. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
3. A novel bispecific antibody, S-Fab, induces potent cancer cell killing.
Li L; He P; Zhou C; Jing L; Dong B; Chen S; Zhang N; Liu Y; Miao J; Wang Z; Li Q
J Immunother; 2015; 38(9):350-6. PubMed ID: 26448579
[TBL] [Abstract][Full Text] [Related]
4. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
5. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
6. Development of a novel bi-specific monoclonal antibody approach for tumour targeting.
Koumarianou AA; Hudson M; Williams R; Epenetos AA; Stamp GW
Br J Cancer; 1999 Oct; 81(3):431-9. PubMed ID: 10507767
[TBL] [Abstract][Full Text] [Related]
7. A novel bispecific antibody, BiSS, with potent anti-cancer activities.
Dong B; Zhou C; He P; Li J; Chen S; Miao J; Li Q; Wang Z
Cancer Biol Ther; 2016 Apr; 17(4):364-70. PubMed ID: 26828900
[TBL] [Abstract][Full Text] [Related]
8. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
9. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
10. Identification of anti-CD16a single domain antibodies and their application in bispecific antibodies.
Zhao Y; Li Y; Wu X; Li L; Liu J; Wang Y; Liu Y; Li Q; Wang Z
Cancer Biol Ther; 2020; 21(1):72-80. PubMed ID: 31564196
[TBL] [Abstract][Full Text] [Related]
11. Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting.
Li Z; Hu Y; An Y; Duan J; Li X; Yang XD
Molecules; 2019 Jan; 24(3):. PubMed ID: 30699986
[TBL] [Abstract][Full Text] [Related]
12. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct.
Schlereth B; Fichtner I; Lorenczewski G; Kleindienst P; Brischwein K; da Silva A; Kufer P; Lutterbuese R; Junghahn I; Kasimir-Bauer S; Wimberger P; Kimmig R; Baeuerle PA
Cancer Res; 2005 Apr; 65(7):2882-9. PubMed ID: 15805290
[TBL] [Abstract][Full Text] [Related]
13. Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity.
Li J; Zhou C; Dong B; Zhong H; Chen S; Li Q; Wang Z
Cancer Biol Ther; 2016 Dec; 17(12):1231-1239. PubMed ID: 27645568
[TBL] [Abstract][Full Text] [Related]
14. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
15. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
16. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
J Biochem; 2006 Sep; 140(3):359-68. PubMed ID: 16861252
[TBL] [Abstract][Full Text] [Related]
17. A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma.
Takemura S; Kudo T; Asano R; Suzuki M; Tsumoto K; Sakurai N; Katayose Y; Kodama H; Yoshida H; Ebara S; Saeki H; Imai K; Matsuno S; Kumagai I
Cancer Immunol Immunother; 2002 Mar; 51(1):33-44. PubMed ID: 11845258
[TBL] [Abstract][Full Text] [Related]
18. Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies.
Kodama H; Suzuki M; Katayose Y; Shinoda M; Sakurai N; Takemura S; Yoshida H; Saeki H; Asano R; Ichiyama M; Imai K; Hinoda Y; Matsuno S; Kudo T
Immunol Lett; 2002 Apr; 81(2):99-106. PubMed ID: 11852114
[TBL] [Abstract][Full Text] [Related]
19. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors.
Brischwein K; Schlereth B; Guller B; Steiger C; Wolf A; Lutterbuese R; Offner S; Locher M; Urbig T; Raum T; Kleindienst P; Wimberger P; Kimmig R; Fichtner I; Kufer P; Hofmeister R; da Silva AJ; Baeuerle PA
Mol Immunol; 2006 Mar; 43(8):1129-43. PubMed ID: 16139892
[TBL] [Abstract][Full Text] [Related]
20. Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells.
Pichinuk E; Benhar I; Jacobi O; Chalik M; Weiss L; Ziv R; Sympson C; Karwa A; Smorodinsky NI; Rubinstein DB; Wreschner DH
Cancer Res; 2012 Jul; 72(13):3324-36. PubMed ID: 22507854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
